MabThera/Rituxan

MSD launches EU’s first biosimilar Herceptin in UK

Roche has particularly high exposure to biosimilar erosion in the coming years in its first-generation antibody products - with Avastin (bevacizumab) and MabThera (rituximab) also under threat along with Herceptin - but

The good, the bad and the ugly

The main drivers of revenue for Roche are well-established, standard-of-care blockbuster oncology drugs including Rituxan, Herceptin and Avastin. ... Humira remains at the top, but Celgene’s Revlimid has jumped ahead of Roche’s Avastin, MabThera and

NICE backs Roche’s Gazyvaro after initial rejection

clinical profile justified premium pricing over Mabthera (rituximab), Roche’s older drug for the FL indication. ... Like MabThera, Gazyvaro targets the CD20 receptor but has been designed with sugar molecule side chains that improve its therapeutic and

Roche faces biosimilar blitz in 2018

Novartis’ unit Sandoz and Celltrion/Mundipharma’s Truxima have also claimed a European approval for its biosimilar versions of Roche’s immunotherapy drug MabThera (rituximab). ... Additionally, Rituxan is expected to plummet by 16% to CHF 6.1bn

Novartis doubles down on biosimilars with Biocon alliance

In the last couple of years it has picked up approvals for Rixathon - a biosimilar of Roche’s cancer and arthritis drug MabThera (rituximab) - as well as its Erelzi version of

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]